Neuroprotective effects of cactus polysaccharide on oxygen and glucose deprivation induced damage in rat brain slices.
1. The neuroprotective effect of cactus polysaccharide (CP) on oxygen and glucose deprivation (OGD) and reoxygenation (REO)-induced damage in the cortical and hippocampal slices of rat brain was investigated. 2. Cell viability was evaluated by using the 2, 3, 5-triphenyl tetrazolium chloride (TTC) method. The fluorescence of propidium iodide (PI) staining was used for quantification of cellular survival, and lactate dehydrogenase (LDH) activity in incubation medium was assessed by LDH assay to evaluate the degree of injury. 3. The OGD ischemic condition significantly decreased cellular viability and increased LDH release in the incubation medium. CP (0.2 mg/l approximately 2 mg/l) protected brain slices from OGD injury in a dosage dependent manner as demonstrated by increased A 490 value of TTC, decreased PI intensity and LDH release. At the above concentration, CP also prevented the increase of nitric oxide (NO) content and inducible nitric oxide synthase (iNOS) activity induced by OGD. 4. CP can protect the brain slices (cortical and hippocampus) against injury induced by OGD. Its neuroprotective effect may be partly mediated by the NO/iNOS system induced by OGD insult.
Huang
Xianju
X
Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Hang Kong Road 13#, Wuhan 430030, China.
Li
Qin
Q
Zhang
Yingpei
Y
Lü
Qing
Q
Guo
Lianjun
L
Huang
Lin
L
He
Zhi
Z
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002545:Brain Ischemia / Q000473:pathology*; D029421:Cactaceae / Q000737:chemistry; D015687:Cell Hypoxia / Q000502:physiology; D002478:Cells, Cultured; D004353:Drug Evaluation, Preclinical; D005947:Glucose / Q000172:deficiency*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D009924:Organ Culture Techniques; D018384:Oxidative Stress / Q000187:drug effects*; D010100:Oxygen / Q000494:pharmacology*; D011134:Polysaccharides / Q000302:isolation & purification / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013778:Tetrazolium Salts / Q000494:pharmacology
D018696:Neuroprotective Agents; D011134:Polysaccharides; D013778:Tetrazolium Salts; D009569:Nitric Oxide; C009591:triphenyltetrazolium; D007770:L-Lactate Dehydrogenase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D005947:Glucose; D010100:Oxygen
Br J Pharmacol. 1992 Aug;106(4):766-7
1382786
Brain Res. 2000 Oct 20;881(1):77-87
11033097
Stroke. 1999 Dec;30(12):2631-6
10582989
Lancet. 1997 Jan 11;349(9045):79-83
8996418
Brain Res Brain Res Protoc. 2001 Feb;6(3):134-40
11223412
J Leukoc Biol. 1994 Nov;56(5):576-82
7525816
Trends Neurosci. 1997 Mar;20(3):132-9
9061868
Science. 1994 Sep 23;265(5180):1883-5
7522345
Nitric Oxide. 1999 Jun;3(3):225-34
10442854
Eur J Neurosci. 1998 Feb;10(2):445-56
9749707
Gen Pharmacol. 1999 May;32(5):577-81
10382860
J Clin Invest. 1997 Nov 15;100(10):2424-9
9366555
J Neurosci Methods. 2000 Jan 15;94(2):187-92
10661838
J Neurosci. 1993 Jun;13(6):2651-61
7684776